E

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E

The BET Bromodomain Landscape in Cancer Research

The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?

May 26, 2016
E

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016
E

Gems from the AACR Poster Hall – Part 2

A look at Bayer's early oncology pipeline and a curious new class called MNK (Mink) inhibitors

May 24, 2016
E

Statistical Challenges of Immunotherapy Clinical Trial Design

What can we learn about clinical trial design from immunotherapy combinations?

May 23, 2016
E

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016
E

Gems from the Poster Hall at AACR16 – Part 1

A look at small biotechs producing quality preclinical data at #AACR16 that may lead to clinical development in the near future

May 12, 2016
E

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016
E

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016
E

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016
E

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
E

Can chemotherapy improve checkpoint blockade in advanced colorectal cancer?

Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition? Early proof of concept in patients with metastatic colorectal cancer.

May 4, 2016
E

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016
E

7 Significant Things I Learned at AACR16 That You Don’t Want to Ignore

What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...

May 2, 2016
E

Thunderbirds are GO!

Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag

April 29, 2016
E

AACR 2016 New Orleans Day 4 Blog

Commentary on Tuesday sessions at AACR 2016 annual meeting

April 19, 2016
E

AACR 2016 New Orleans Day 3 Blog

Commentary on Monday at AACR 2016 annual meeting

April 18, 2016
E

AACR 2016 New Orleans Day 2 Blog

Commentary from Sunday at 2016 AACR annual meeting

April 17, 2016
E

AACR 2016 New Orleans Day 1 Blog

Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.

April 16, 2016
E

What next for Bcl2 inhibitors after venetoclax’s approval in CLL?

Where next for Bcl2 inhibitors beyond CLL and Del17p? Which novel combinations might be an attractive strategy?

April 13, 2016
E

AACR 2016 CD40 Cancer Immunotherapy

In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).

April 8, 2016
E

OX40 immune agonists at AACR 2016

Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.

April 7, 2016
E

AACR 2016 GITR Cancer Immunotherapy

There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.

April 6, 2016
E

AACR 2016 Cancer Immunotherapy Targeting IDO1 TDO

This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.

April 5, 2016
E

Targeting Acquired Resistance in Prostate Cancer

The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.

April 4, 2016
E

AACR 2016 A Preview of anti TIM-3 and LAG-3 Checkpoints

A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR

April 1, 2016
E

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016
E

Future of Cancer Immunotherapy

Commentary on some of the latest cancer immunotherapy papers

March 29, 2016
E

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016
E

Top 10 Abstracts at AACR 2016

Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions

March 17, 2016
E

What’s Hot at AACR 2016? Annual Meeting Preview 1

Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.

March 16, 2016
E

Making CAR T cell therapy more effective in leukemia and solid tumors

Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...

March 15, 2016